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Abstract
Human T-lymphotropic virus type-1 (HTLV-1) is a complex retrovirus that causes adult T-cell
leukemia/lymphoma (ATL) and is implicated in a variety of lymphocyte-mediated disorders. HTLV-
1 pX ORF II encodes two proteins, p13II and p30II whose roles are beginning to be defined in the
virus life cycle. Previous studies indicate the importance of these viral proteins in the ability of the
virus to maintain viral loads and persist in an animal model of HTLV-1 infection. Intriguing new
studies indicate that p30II is a multifunctional regulator that differentially modulates CREB and Tax-
responsive element-mediated transcription through its interaction with CREB-binding protein
(CBP)/p300 and specifically binds and represses tax/rex  mRNA nuclear export. A new study
characterized the role of p30II in regulation of cellular gene expression using comprehensive human
gene arrays. Interestingly, p30II is an overall repressor of cellular gene expression, while selectively
favoring the expression of regulatory gene pathways important to T lymphocytes. These new
findings suggest that HTLV-1, which is associated with lymphoproliferative diseases, uses p30II to
selectively repress cellular and viral gene expression to favor the survival of cellular targets
ultimately resulting in leukemogenesis.
The complex sequence of events set in motion by human
T-lymphotropic virus type 1 (HTLV-1) to cause prolifera-
tion and ultimately transformation of T lymphocytes is
beginning to be unraveled. Only recently has it become
clear that viral encoded proteins, the so-called "accessory"
gene products of this complex retrovirus, play an integral
role in the pathogenic process. In addition to the struc-
tural and enzymatic gene products, HTLV-1 encodes regu-
latory and accessory proteins from four open reading
frames (ORF) in the pX region between env and the 3' long
terminal repeat (LTR) of the provirus [1,2]. The well stud-
ied Rex and Tax positive regulators are encoded in the
ORF III and IV, respectively. Rex plays a critical role in
nuclear export of unspliced or singly spliced viral mRNA
[3,4]. Tax orchestrates multiple interactions with cellular
transcription factors and activates transcription from the
viral promoter and modulates the transcription or activity
of numerous cellular genes involved in cell growth and
differentiation, cell cycle control, and DNA repair [5,6].
Recent studies have indicated novel roles for pX ORF I and
II gene products in the replication of HTLV-1 [7-9].
Although the study of these gene products were largely by-
passed by virologists until the mid 1990's, they intensified
when infectious molecular clones provided the tools to
better understand their role in vivo. Both HTLV-1 pX ORF
I and II mRNAs have been detected in infected cell lines
and blood leukocytes from HTLV-1-infected subjects
including ATL and HAM/TSP patients [10,11]. Also,
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immune responses of HTLV-1 infected patients and
asymptomatic carriers indicate that these proteins are
expressed in vivo [12-14].
Molecular clones of HTLV-1 with selective mutations of
ORF I and II have revealed the requirement of p12I and
p13II/p30II in the establishment of infection and mainte-
nance of viral loads in a rabbit model of infection [15-17].
The nuclear and nucleolar localizing p30II has minimal
homology to transcription factors Oct-1 and -2, Pit-1, and
POU-M1 [18-21]. In addition, the protein co-localizes
with p300 in the nucleus and physically interacts with
CREB binding protein (CBP)/p300 and differentially
modulates cAMP responsive element (CRE) and Tax
response element-mediated transcription [21,22]. Intrigu-
ing recent reports also indicate a post-transcriptional role
of HTLV-1 p30II and HTLV-2 p28II(homologous protein
encoded in the HTLV-2 pX ORF II region), in repressing
the export of tax/rex  mRNA from the nucleus [23,24].
Thus, it appears that HTLV-1 has yet another multifunc-
tional protein with transcriptional and post-transcrip-
tional roles in regulating viral gene expression.
Microarrays are important tools to gain insight into
changes in gene expression profiles of virus-infected cells.
This approach has been primarily used to investigate gene
expression in HTLV-1-immortalized/transformed cell
lines or in cells from ATL patients [25-29]. In the report by
Michael et al. [30] the authors used the Affymetrix U133A
human gene chip to test the role of HTLV-1 p30II as a reg-
ulator of gene expression in Jurkat T cells. They identified
alterations in gene expression profiles unique to cell cycle
regulation, apoptosis, and T lymphocyte signaling/activa-
tion. Although p30II expression, as might be expected
from earlier reports, resulted in a general repressive pat-
tern of gene expression, their data indicated that the viral
protein selectively spared or enhanced NFAT, NFκB, and
AP-1 mediated transcription in T cells undergoing co-
stimulation. Signaling pathways primarily affected by
p30II as measured by luciferase reporters included both
NFAT and NFκB, which increased from approximately 3
to 11 fold, depending on co-stimulatory treatment. Over-
all, this study supports earlier reports on the repressive
role of HTLV-1 p30II  in gene expression [21-24] and
reveals new potential mechanisms by which p30II may
play a role in HTLV-1 replication (figure 1). The effects of
p30II appear to overlap or counteract the influence of
other HTLV-1 regulatory proteins like Tax or other acces-
sory proteins such as p12I. Further studies to test if these
proteins act coordinately or synergistically will undoubt-
edly shed light on this issue. It is possible that HTLV-1
employs selective use of these viral proteins during vari-
ous stages of the infection to promote cell proliferation, a
hallmark of the diseases associated with the deltaretrovi-
rus family. Whatever the outcome of these studies, it is
clear that "accessory" proteins, like p30II, may have
"essential" roles in the life cycle of HTLV-1.
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Model for HTLV-1 p30II transcriptional and posttranscrip- tional gene regulation Figure 1
Model for HTLV-1 p30II transcriptional and posttranscrip-
tional gene regulation. The cell nucleus surrounded by the 
nuclear membrane and key components are shown. p30II can 
directly interact with CBP/p300 and modulate transcription 
of viral and/or cellular genes. At low concentration p30II may 
stabilize the transcription complex and potentiate transcrip-
tion, whereas a high concentration it may compete for lim-
ited amounts of CBP/p300 and repress gene expression. p30II 
(as well as the homologous p28II of HTLV-2) specifically binds 
tax/rex mRNA and block its export, reducing Tax and Rex 
and ultimately repressing viral gene expression. This interac-
tion may be directly linked to splicing factors and splicing 
and/or the juxtaposition of specific exon/exon junction 
sequences. Thus, p30II is a multifunctional protein with tran-
scriptional and post-transcriptional roles in regulating viral 
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